DELL vs PFE: Which Is the Better Buy?
Side-by-side comparison of Dell Technologies Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-10.
Dell Technologies Inc. · Technology
$450.22
-13.0% upside to fair value
Grade D
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DELL |
PFE |
| Current Price |
$450.22 |
$25.22 |
| Fair Value Estimate |
$391.48 |
$25.92 |
| Upside to Fair Value |
-13.0%
|
+2.8%
|
| Market Cap |
$299.1B |
$143.7B |
| Forward P/E |
35.2x
|
19.2x
|
| EV / EBITDA |
22.9x
|
12.3x
|
| Price / Sales |
2.2x
|
2.3x
|
| Price / FCF |
31.7x
|
15.2x
|
| Revenue Growth YoY |
+87.5%
|
+5.4%
|
| Gross Margin |
19.2%
|
69.3%
|
| Operating Margin |
8.0%
|
23.4%
|
| Return on Equity |
-363.2%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.16%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Dell Technologies Inc. operates in the technology sector focusing on computer hardware, delivering strong revenue and earnings growth in the most recent quarter with 87.5% and 256.3% year-over-year increases respectively. Despite these impressive growth metrics and a solid operating margin of 8.0%, the company is currently overvalued with its stock trading 13% above the fair value estimate of $39…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
DELL |
PFE |
| Zone Low |
$293.61 |
$19.44 |
| Zone High |
$332.76 |
$22.03 |
| In Buy Zone? |
No
|
No
|